BLACK WEEKSFrascos −15% · kits −10% · resto −5%com o códigoEnvio grátis na Alemanha a partir de 200 €

Esta página foi traduzida automaticamente e pode conter erros. É falante nativo? Agradecemos o seu feedback e as suas correções.Enviar feedback

The Peptide Desk The Peptide Desk
Insulin Glargin (Lantus), foto do produto
Medication

Insulin Glargin (Lantus)

Medication

  • Enviado da Alemanha

Encomenda

Preço unitário - Envio grátis na Alemanha a partir de 200 € durante as Black Weeks
  • DHL com seguimento
  • Embalagem discreta

4.6 de 5 no Trustpilot73 avaliações

Num relance

Insulin Glargin (Lantus) em números

Os valores-chave da nossa enciclopédia.

Entrada completa da enciclopédia
Class
Long-acting insulin analoguebasal insulin
Use
Subcutaneous1x daily at a fixed time of day
Sizes
3ml/300iu1 size in the shop

Ainda não existe análise laboratorial para Insulin Glargin (Lantus). Vote neleTodas as análises laboratoriais

Conhecimento

Tudo sobre Insulin Glargin (Lantus)

FAQ

Perguntas frequentes

Fontes de cada resposta: entrada da enciclopédia

Ainda tem alguma pergunta?

Escreva-nos, a nossa equipa ajuda.

Why does Insulin Glargine act so long?

Under the skin glargine forms a fine depot and dissolves slowly. In a 24-hour clamp the effect began after about 1.5 hours, there was no peak and it ended after about 22 hours. NPH insulin peaked at 4.5 hours and ended after 14 hours.

Is Insulin Glargine approved?

Yes. ChEMBL lists Insulin Glargine as an approved drug with first approval in 2000. On ClinicalTrials.gov more than 700 trials list Insulin Glargine among their interventions (as of 25 October 2026). Everything here is the state of research, not a recommendation.

Is there less hypoglycaemia than with NPH insulin?

In two large comparisons yes. In 534 adults with type 1 diabetes 18.2 instead of 27.1 percent had night-time hypoglycaemia. In 756 people with type 2 diabetes 33.2 instead of 26.7 percent reached the target without night-time hypoglycaemia while the long-term value was practically the same with both insulins.

What did the ORIGIN trial show?

12,537 people with cardiovascular risk and impaired glucose metabolism received glargine or standard care for a median of 6.2 years. Cardiovascular events and cancer did not differ. Severe hypoglycaemia was more than three times as common at 1.00 versus 0.31 per 100 person-years and weight rose by a median of 1.6 kg instead of falling by 0.5 kg.

Does glargine act the same every day?

Not quite. Under clamp conditions the effect varied less from day to day with glargine than with NPH insulin but more than with insulin detemir (coefficient of variation over 24 hours 48 versus 68 and 27 percent). A flat average profile does not rule out deviations in individual cases.

What is the biggest risk?

Hypoglycaemia over a long action window. A depot under the skin cannot be retrieved, too high a dose keeps acting for about a day. Even in ORIGIN with medical supervision severe hypoglycaemia was more than three times as common as without glargine.

Relacionados

Produtos relacionados